Print

LifeSensors Inc. Launches their Ubiquitin Pathway Enzymes Assay Kits Licensed from Progenra, Inc.  
7/10/2009 8:53:13 AM

MALVERN, Pa.--(BUSINESS WIRE)--LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools and protein microarrays, announced today the launch of their CHOP2 Reporter assay kits for deubiquitylases (DUBs) and the imminent launch of their ubiquitin ligase assay kits. These proprietary technologies were developed by and licensed from Progenra, Inc. (www.progenra.com). The conjugation and deconjugation of ubiquitin and ubiquitin-like proteins (UBLs) are areas of intense interest within the academic and pharmaceutical communities due to their central roles in human heath and disease. It is likely that many pioneering drugs will emerge from research on ubiquitin and ubiquitin-like protein pathways. The assay platforms will aid in the identification and further characterization of the approximately 100 DUBs and 700 ligases in the human genome. Ongoing drug discovery and development programs by Progenra and others demonstrates the utility of these assay platforms to identify and characterize novel modulators of DUBs and ligases.
//-->